GDB and its wholly-owned subsidiary (www.shenoxpharma.com) focus on development of novel drugs for treatment of central nervous system (CNS) diseases, primarily based on a transdermal drug delivery system (TDDS), and cardiovascular (CV)/metabolic diseases primarily based on advanced oral technology for delivery of large molecules. Most programs follow the regulatory pathway of Category II in China and 505b(2) in the U.S.

 

GDB pipeline emphasizes global values with significant differentiation from competitors in both medicinal compounds and drug delivery systems. SHX-001 is the first and only transdermal delivery system of racemic ketamine for the treatment of major depressive disorders (MDD). SHX-020 is the oral form of heparin with good bioavailability and PK profile intended for the treatment and prophylaxis of  vein thrombosis. SHX-021 is an oral GLP-1 RA developed for the treatment of diabetes and management of obesity, demonstrating superior oral bioavailability and substantially reduced variability in oral absorption and pharmacokinetics (PK).

 

GDB has developed a wholly-owned delivery platform for the effective oral administration of large molecules (MO-PION) with global intellectual property protection. GDB’s PIG-PERM is a leading specialty platform for evaluating the development of innovative TDDS and enabling accurate translation of TDDS absorption and pharmacokinetics from animals to humans. 

About us

News

learn more